Towa Pharmaceutical Integrated Report 2026

As an integrated report, it covers the company’s business and sustainability initiatives in fiscal 2025, including the expansion of its stable supply framework, collaboration with other companies, and measures to address nitrosamines. The governance structure and changes from the previous report cannot be confirmed in the provided text.

Worth reading

—

Scored from 0 of 5 sections

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Conditional

How definitive the wording is.

Contents of this filing

This filing does not state the corporate governance structure or the composition of the board of directors.

Items this document does not state (8)

Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To address challenges facing the pharmaceutical industry and society, including concerns over the supply of medicines, quality issues, changes in the drug pricing system, and extending healthy life expectancy.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.